Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials.

Front Oncol · 2021 · PMC7947606 · PMID 33718135

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Furthermore, pneumonitis ( P = 0.150 ), hypopituitarism ( P = 0.110 ), and decreased appetite ( P = 0.200 ) showed a trend towards increased risk in patients treated with ICI-based combination therapy as compared with monotherapy but did not differ significantly.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.